VKTX — Viking Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1607678 ·
Last close
$35.56
Market Cap
$4.15B
52W High
$43.15
52W Low
$24.88
ADV30
5,055,807
Next earnings
2026-10-28
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -132,597,000 | -128,022,000 | 521,898,000 | 125,750,000 | — |
| Mar 2026 | 0 | — | -164,125,000 | -158,325,000 | 608,242,000 | 118,116,000 | 106,325,000 |
| Dec 2025 | 0 | — | -164,738,000 | -157,662,000 | 715,729,000 | 165,810,000 | 76,667,000 |
| Sep 2025 | 0 | — | -98,561,000 | -90,787,000 | 739,415,000 | 100,376,000 | 26,385,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-418,441,000
Investing CF
$399,257,000
Financing CF
$111,246,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.66
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,133,893,000
Inventory
—
Receivables
—
ST Investments
$375,913,000
EBIT TTM
$-560,021,000
Pretax Income TTM
$-534,796,000
Interest Exp TTM
—
Analysts
19
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -393,342,000 | -359,639,000 | 715,729,000 | 76,667,000 | 639,062,000 | -278,685,000 |
| Dec 2024 | 0 | -150,921,000 | -109,963,000 | 908,321,000 | 28,043,000 | 880,278,000 | -87,790,000 |
| Dec 2023 | 0 | -100,827,000 | -85,895,000 | 368,490,000 | 20,071,000 | 348,419,000 | -73,376,000 |
| Dec 2022 | 0 | -70,355,000 | -68,867,000 | 168,529,000 | 23,207,000 | 145,322,000 | -48,397,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.32
Max Pain — expiry 2026-10-02
max pain strike: $34.00 · spot: $35.56 · call oi: 17,419 · put oi: 6,286
Expected Move to 2026-10-02:
±$2.63
(7.40%) —
implied range
$32.93 –
$38.19
· ATM straddle on $35.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $4.12B | $12.70 | — |
| TNGX | Tango Therapeutics, Inc. | $4.20B | $24.92 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | $35.82 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.27B | $39.34 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.89B | $11.45 | — |
News headlines (Yahoo Finance, 1h cache)
Viking Therapeutics (VKTX) Delivers Great VK2735 Results: Here's a Word of Caution
2026-09-27 14:20 · Yahoo
3 Numbers From Viking Therapeutics' Weight-Loss Drug Trial That Have Wall Street Buzzing
2026-09-27 09:15 · Yahoo
Is Viking Therapeutics (VKTX) Getting Too Rich After VK2735 Data?
2026-09-25 19:09 · Yahoo
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy?
2026-09-25 10:25 · Yahoo
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-09-24 20:45 · Yahoo
One investor reportedly took a third of Viking’s share sale
2026-09-24 17:48 · Yahoo
Here's Why Viking Therapeutics Shares Slumped Today
2026-09-24 15:50 · Yahoo
Viking Therapeutics Sinks 12% on “Upsized” $500 Million Raise
2026-09-24 14:24 · Yahoo
Viking Therapeutics Sinks 15% After Pricing Upsized $500M Offering; Jaguar Health Tumbles 25%
2026-09-24 14:23 · Yahoo
VKTX Stock Heads Toward Worst Day In Over A Year Just Days After Promising Weight Loss Drug Data — Here’s What’s Driving The Selloff
2026-09-24 12:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.